|
Workshop
[In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
Speakers:
Mohan Srinivasan (Loxo/Lilly), Thomas Pillow (Genentech), Bernhard Geierstanger (Firefly Biologics), Laurence Fayadat-Dilman (Merck), Travis Biechele (Shasqi), Judy Hsii (SutroBio), Hui Zhao (Exelixis), Sara Glickstein Bar-Zeev (Genentech), Maya Skubatch (Wilson Sonsini)
Organizers:
Mohan Srinivasan (Loxo Oncology at Lilly), Thomas Pillow (Genentech), Laurence Fayadat-Dilman (Merck)
Date:
2024-03-28
Time:
8:45-17:30 Pacific Time
Registration fee:
Regular attendees: $295; Academic/Students/Postdocs: $45; Out-of-Pocket: $45; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $975; Lunch Sponsorship: $1250; On-site Registration: $500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(28)Abzena; Altruist Biologics; AsymBio; Aton Biotech; BioAgilytix; Biocytogen Boston Corp; BioIVT; Biomere; BioTether Sciences; Celerion; Cellentia Inc.; ChemPartner Shanghai; Correlia Biosystems Inc; Curia; Discovery Life Sciences; Emery Pharma; Gator Bio; JOINN Biologics Us Inc.; KACTUS; KCAS Bio; Lonza; Meadowhawk Biolabs; Milliporesigma; Mycenax; Nanotemper; newcells biotech; PharmaBlock; Pharmalegacy
Registration: http://www.PBSS.org
Registration deadline:2024-03-27
(it will close sooner if the seating cap is reached)
About the Topic
Sponsored by Resolian, Alturas Analytics, Mycenax
Topics:
- ADC overview
- Target selection
- Chemistry of linker payload & conjugation techniques
- Antibody Engineering for ADCs
- Analytical and Biophysical Characterization of ADCs
- In-vitro and in-vivo activity considerations for ADCs
- CMC Challenges and Opportunities in ADCs
- PK and Toxicology Study Designs
- Clinical Trial Design for ADCs
- Intellectual Property of ADCs
| Time (PST) |
Topic |
Speaker |
| 8:45 am - 8:55 am |
PBSS Welcome Remarks |
Shichang Miao, PhD, PBSS |
| 8:55 am - 9:15 am |
Workshop Overview and ADC overview |
Mohan Srinivasan, PhD, Associate VP, Biologics, Loxo/Lilly |
| 9:15 - 9:35 am |
ADC Target Characterization and Selection Strategies |
Travis Biechele, PhD, VP of Research at Shasqi |
| 9:35 am - 10:20 am |
Chemistry of Linker Payload & Conjugation Techniques |
Thomas Pillow, PhD, Distinguished Scientist, Genentech |
| 10:20 am - 11:05 am |
Antibody Engineering for ADCs |
Bernhard Geierstanger, PhD, Co-Founder and CTO, Firefly Biologics |
| 11:05 am - 11:15 am |
Major Sponsor Presentation |
Resolian |
| 11:15 am - 11:35 am |
Break and Vendor Show |
- |
| 11:35 am - 12:20 pm |
Analytical and Biophysical Characterization of ADCs |
Laurence Fayadat-Dilman, PhD, Executive Director, Discovery Biologics, Merck |
| 12:20 pm - 1:10 pm |
Lunch Break |
Sponsor (Mycenax) |
| 1:10 pm - 1:40 pm |
In-vitro and In-vivo Pharmacology for ADCs |
Travis Biechele, PhD, Senior Principal Scientist, Merck |
| 1:40 pm - 2:25 pm |
CMC Challenges and Opportunities in ADCs |
Judy Hsii, MS, Executive Director, Sutro Biopharma |
| 2:25 pm - 3:10 pm |
PK and Toxicology Study Designs |
Hui Zhao, PhD, Senior Director of Translational Biology, Exelixis |
| 3:10 pm - 3:20 pm |
Major Sponsor Presentation |
Alturas Analytics |
| 3:20 pm - 3:40 pm |
Break and Vendor Show |
- |
| 3:40 pm - 4:20 pm |
Clinical Trial Design for ADCs |
Sara Glickstein Bar-Zeev, PhD, Principal Clinical Scientist, Genentech |
| 4:20 pm - 5:00 pm |
Intellectual Property of ADCs |
Maya Skubatch, JD, Partner at Wilson Sonsini Goodrich & Rosati |
| 5:00 pm - 5:30 pm |
Panel Discussion & Closing Remarks |
All Speakers |
| 5:30 PM - 6:30 pm |
Happy Hour |
Sponsor (Correlia Biosystems) |
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: Untangling What We Thought We Knew and Future Precision Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro Delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Submit a Text Ad
|